55 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptorß agonists.
Eli Lilly
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.
Phenex Pharmaceuticals
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptorß agonist in clinical trials for the treatment of dyslipidemia.
Madrigal Pharmaceuticals
Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptorß agonists.
Sanwa Kagaku Kenkyusho
Development of novel Vitamin D Receptor-Coactivator Inhibitors.
University of Wisconsin-Milwaukee
Synthesis and evaluation of methylsulfonylnitrobenzamides (MSNBAs) as inhibitors of the thyroid hormone receptor-coactivator interaction.
St. Jude Children'S Research Hospital
Identification of Potent and Selective Diphenylpropanamide RORγ Inhibitors.
New York University School of Medicine
Design, synthesis, and structure-activity relationship (SAR) of N-[7-(4-hydroxyphenoxy)-6-methylindan-4-yl]malonamic acids as thyroid hormone receptorß (TRß) selective agonists.
Kissei Pharmaceutical
Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.
Zydus Research Centre
Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors.
Institut Pasteur Korea
Discovery of novel indane derivatives as liver-selective thyroid hormone receptorß (TRß) agonists for the treatment of dyslipidemia.
Kissei Pharmaceutical
Characterization of thyroid hormone receptor alpha (TRalpha)-specific analogs with varying inner- and outer-ring substituents.
University of California San Francisco
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.
Abbott Laboratories
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors.
St. Jude Children'S Hospital
Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.
Metabasis Therapeutics
Design and synthesis of novel 3-hydroxy-cyclobut-3-ene-1,2-dione derivatives as thyroid hormone receptor beta (TR-beta) selective ligands.
Zydus Research Centre
Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index.
Metabasis Therapeutics
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Eli Lilly and Company
Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH.
Aligos Belgium BV
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications.
Ludwig Maximilian University of Munich
Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Shanghai Institute of Materia Medica
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Institute of Mit and Harvard
Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.
Guangzhou Institutes of Biomedicine and Health
Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta.
Karo Bio
A new class of high affinity thyromimetics containing a phenyl-naphthylene core.
Pharmaceutical Research Institute
Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.
Pfizer
Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.
University of California
Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
University of Pisa
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
Tes Pharma
Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.
Karo Bio
l-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPARγ.
Goethe-University Frankfurt
SMALL MOLECULE INHIBITORS OF NAV1.8 SODIUM CHANNELS FOR PAIN RELIEF
Humanwell Pharmaceutical US
PYRROLO[3,2-B]PYRIDINE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS
Novartis
Compound used as Bruton's tyrosine kinase inhibitor and preparation method and application thereof
Chengdu Brilliant Pharmaceutical
Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
Viiv Healthcare UK (NO.5)
Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors
Bristol-Myers Squibb
Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
Incyte